• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Milestone Scientific Inc.

    4/22/26 7:53:45 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0000855683
    U S OPPORTUNITY SEARCH, INC
    MILESTONE SCIENTIFIC INC/NJ
    U S OPPORTUNITY SEARCH INC
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     MILESTONE SCIENTIFIC INC.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     MILESTONE SCIENTIFIC INC.
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE
     SUITE 403
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     ROSELAND
     NEW JERSEY
     
     07068
     973-535-2717 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Hines
    Eric
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Executive Officer



    Last NameFirst NameMiddle Name
    Harcum
    Keisha
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Vice President of Finance



    Last NameFirst NameMiddle Name
    Casamento
    Benedetta
    I.
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chairman of the Board



    Last NameFirst NameMiddle Name
    Goldman
    Neal
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Demesmin
    Didier
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Thiyagalingam
    Shanth
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Sayed
    Dawood
    Street Address 1Street Address 2
     425 EAGLE ROCK AVENUE 
     SUITE 403
    CityState/Province/CountryZIP/Postal Code
     ROSELAND
     NEW JERSEY
     07068
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-04-20
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox not checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     25000
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     
     
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number  Checkbox not checkedNone
     
     
    Street Address 1Street Address 2
     
     
    City State/Province/CountryZIP/Postal Code
     
     
     
    State(s) of Solicitation Checkbox not checkedAll States
     



    13. Offering and Sales Amounts
     
    Total Offering Amount $
    4837500
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    2150000
    USD
    Total Remaining to be Sold $
    2687500
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    Total Offering Amount includes $2,687,500 of potential proceeds payable upon the exercise of warrants issued in the offering. Total Amount Sold includes $1,799,000 in cash and $351,000 from conversion of a portion of certain convertible bridge notes.
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    21
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    0
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    MILESTONE SCIENTIFIC INC./s/ Eric HinesEric HinesChief Executive Officer2026-04-22




    Get the next $MLSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    SEC Filings

    View All

    SEC Form D filed by Milestone Scientific Inc.

    D - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    4/22/26 7:53:45 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    4/21/26 9:36:42 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    4/2/26 3:41:03 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Scientific Inc. Completes $2.15 Million Private Placement

    ROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of a $2.15 million private placement of common stock and warrants, and an additional $2.69 million if cash warrants are fully exercised. "Today we strengthened our balance sheet and positioned the company to capitalize on the increasing demand we are seeing across our product platforms," said Eric Hines, Chief Executive Officer of Milestone Scientific. "This financing allows us to build on our progress, scaling investment in sales, inventory and digital marketing, wh

    4/21/26 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025

    Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: "When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent execut

    3/31/26 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 875878. A webcast and replay of the

    3/26/26 9:00:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bp4 S.R.L. sold $84,884 worth of shares (194,427 units at $0.44), decreasing direct ownership by 2% to 8,896,765 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/29/25 4:29:34 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $28,472 worth of shares (64,034 units at $0.44), decreasing direct ownership by 0.70% to 9,091,192 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/23/25 4:49:27 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $27,273 worth of shares (50,158 units at $0.54), decreasing direct ownership by 0.44% to 9,155,226 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/17/25 4:39:17 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Financials

    Live finance-specific insights

    View All

    Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025

    Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: "When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent execut

    3/31/26 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 875878. A webcast and replay of the

    3/26/26 9:00:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati

    11/13/25 4:00:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management

    ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca

    9/22/25 9:15:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer

    ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m

    8/1/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care